000 03205nam a22003855i 4500
001 310051
003 MX-SnUAN
005 20160429160338.0
007 cr nn 008mamaa
008 150903s2005 sz | o |||| 0|eng d
020 _a9783764373054
_99783764373054
024 7 _a10.1007/b137043
_2doi
035 _avtls000362683
039 9 _a201509031114
_bVLOAD
_c201405070505
_dVLOAD
_y201402211055
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aRM1-950
100 1 _aSpanagel, Rainer.
_eeditor.
_9345152
245 1 0 _aDrugs for Relapse Prevention of Alcoholism /
_cedited by Rainer Spanagel, Karl F. Mann.
264 1 _aBasel :
_bBirkhäuser Basel,
_c2005.
300 _axii, 243 páginas
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aMilestones in Drug Therapy MDT
500 _aSpringer eBooks
505 0 _aHistory of prevention of relapse -- How to measure relapse in animals -- How to measure relapse in humans -- Disulfiram (Antabuse®): the first medication to stop drinking -- Naltrexone: preclinical data -- Naltrexone: clinical data -- Acamprosate: preclinical data -- Acamprosate: clinical data -- Serotonergic compounds: preclinical data -- Serotonergic compounds: clinical data -- Opioidergic compounds: preclinical data -- Second generation opioidergic compounds: clinical data -- Dopaminergic compounds: preclinical data -- Dopaminergic compounds: clinical data -- Baclofen: preclinical data -- Baclofen: clinical data -- Cannabinoid receptor antagonists: a perspective -- Neuropeptide Y antagonists: a perspective -- Glutamatergic compounds: a perspective -- Future perspectives on relapse prevention.
520 _aThe field of biomedical research on alcoholism has developed at an astonishing speed in recent years. Today, new medications and treatment strategies are available and new leads are currently tested in multi-center trials. This book gives a comprehensive overview about different neurotransmitter/peptide systems involved in craving and relapse behavior and critically describes the clinical application of new anti-craving and anti-relapse compounds. The editors - a preclinical researcher and a clinical researcher, together with some of the most distinguished experts in the field - compiled the most recent available preclinical and clinical data, offering a thorough picture on modern relapse prevention. Undoubtedly, this book sets out to provide an all-encompassing overview about the topic, which will be of interest to the preclinical researcher, the clinician as well as to the patient who wants to learn more.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700 1 _aMann, Karl F.
_eeditor.
_9350601
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9783764302146
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/b137043
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c310051
_d310051